{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:17:46Z","timestamp":1793830666469,"version":"4.6.1"},"reference-count":230,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-024-00580-4","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T03:01:48Z","timestamp":1734577308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Guillain\u2013Barr\u00e9 syndrome"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-6926","authenticated-orcid":false,"given":"Sonja E.","family":"Leonhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowshin","family":"Papri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nortina","family":"Shahrizaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-2458","authenticated-orcid":false,"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"580_CR1","first-page":"24","volume":"150","author":"G Guillain","year":"1999","unstructured":"Guillain, G., Barr\u00e9, J. A. & Strohl, A. Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916 [French]. Ann. Med. Interne 150, 24\u201332 (1999). The first report on the CSF findings in patients with acute flaccid paralysis that were distinctive from poliomyelitis.","journal-title":"Ann. Med. Interne"},{"key":"580_CR2","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs, B. C. et al. The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study. Neurology 51, 1110\u20131115 (1998).","journal-title":"Neurology"},{"key":"580_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1605564","volume":"375","author":"B Parra","year":"2016","unstructured":"Parra, B. et al. Guillain-Barr\u00e9 syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513\u20131523 (2016).","journal-title":"N. Engl. J. Med."},{"key":"580_CR4","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/brain\/awy232","volume":"141","author":"AY Doets","year":"2018","unstructured":"Doets, A. Y. et al. Regional variation of Guillain-Barre syndrome. Brain 141, 2866\u20132877 (2018). A description of clinical features and outcome of patients with GBS in a large international cohort study.","journal-title":"Brain"},{"key":"580_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/brain\/115.4.1093","volume":"115","author":"F Grand\u2019Maison","year":"1992","unstructured":"Grand\u2019Maison, F., Feasby, T. E., Hahn, A. F. & Koopman, W. J. Recurrent Guillain-Barr\u00e9 syndrome. Clinical and laboratory features. Brain 115, 1093\u20131106 (1992).","journal-title":"Brain"},{"key":"580_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.2008.156463","volume":"80","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K., van Koningsveld, R., Ruts, L., Jacobs, B. C. & van Doorn, P. A. Recurrent Guillain-Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 80, 56\u201359 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jns.2016.03.008","volume":"364","author":"J Ishii","year":"2016","unstructured":"Ishii, J., Yuki, N., Kawamoto, M., Yoshimura, H., Kusunoki, S. & Kohara, N. Recurrent Guillain-Barr\u00e9 syndrome, Miller Fisher syndrome and Bickerstaff brainstem encephalitis. J. Neurol. Sci. 364, 59\u201364 (2016).","journal-title":"J. Neurol. Sci."},{"key":"580_CR8","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","volume":"30","author":"PA van Doorn","year":"2023","unstructured":"van Doorn, P. A. et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barre syndrome. Eur. J. Neurol. 30, 3646\u20133674 (2023). An evidence-based guideline for the diagnosis and treatment of GBS using GRADE methodology with joint task forces of the EAN and the PNS.","journal-title":"Eur. J. Neurol."},{"key":"580_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jns.12594","volume":"28","author":"PA van Doorn","year":"2023","unstructured":"van Doorn, P. A. et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barre syndrome. J. Peripher. Nerv. Syst. 28, 535\u2013563 (2023).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jns.12209","volume":"22","author":"BC Jacobs","year":"2017","unstructured":"Jacobs, B. C. et al. International Guillain-Barr\u00e9 Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barr\u00e9 syndrome. J. Peripher. Nerv. Syst. 22, 68\u201376 (2017).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"388","author":"HJ Willison","year":"2016","unstructured":"Willison, H. J., Jacobs, B. C. & van Doorn, P. A. Guillain-Barre syndrome. Lancet 388, 717\u2013727 (2016).","journal-title":"Lancet"},{"key":"580_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","volume":"36","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J., Baughman, A. L., Wise, M. & Morgan, O. W. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 36, 123\u2013133 (2011). A systematic review and meta-analysis on the population incidence of GBS in the Northern hemisphere.","journal-title":"Neuroepidemiology"},{"key":"580_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000184748","volume":"32","author":"A McGrogan","year":"2009","unstructured":"McGrogan, A., Madle, G. C., Seaman, H. E. & de Vries, C. S. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 32, 150\u2013163 (2009).","journal-title":"Neuroepidemiology"},{"key":"580_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41582-021-00467-y","volume":"17","author":"N Papri","year":"2021","unstructured":"Papri, N. et al. Guillain-Barre syndrome in low-income and middle-income countries: challenges and prospects. Nat. Rev. Neurol. 17, 285\u2013296 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"580_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1600-0404.1996.tb00169.x","volume":"93","author":"WP Howlett","year":"1996","unstructured":"Howlett, W. P., Vedeler, C. A., Nyland, H. & Aarli, J. A. Guillain-Barr\u00e9 syndrome in northern Tanzania: a comparison of epidemiological and clinical findings with western Norway. Acta Neurol. Scand. 93, 44\u201349 (1996).","journal-title":"Acta Neurol. Scand."},{"key":"580_CR16","first-page":"21","volume":"43","author":"Z Melaku","year":"2005","unstructured":"Melaku, Z., Zenebe, G. & Bekele, A. Guillain-Barre syndrome in Ethiopian patients. Ethiop. Med. J. 43, 21\u201326 (2005).","journal-title":"Ethiop. Med. J."},{"key":"580_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-0404.2011.01503.x","volume":"125","author":"ME Dourado","year":"2012","unstructured":"Dourado, M. E., Felix, R. H., da Silva, W. K., Queiroz, J. W. & Jeronimo, S. M. Clinical characteristics of Guillain-Barre syndrome in a tropical country: a Brazilian experience. Acta Neurol. Scand. 125, 47\u201353 (2012).","journal-title":"Acta Neurol. Scand."},{"key":"580_CR18","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1136\/jnnp-2014-309056","volume":"86","author":"AJ Webb","year":"2015","unstructured":"Webb, A. J., Brain, S. A., Wood, R., Rinaldi, S. & Turner, M. R. Seasonal variation in Guillain-Barre syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J. Neurol. Neurosurg. Psychiatry 86, 1196\u20131201 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/brain\/118.3.597","volume":"118","author":"TW Ho","year":"1995","unstructured":"Ho, T. W. et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118, 597\u2013605 (1995).","journal-title":"Brain"},{"key":"580_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3201\/eid1707.101999","volume":"17","author":"Z Islam","year":"2011","unstructured":"Islam, Z. et al. High incidence of Guillain-Barre syndrome in children, Bangladesh. Emerg. Infect. Dis. 17, 1317\u20131318 (2011).","journal-title":"Emerg. Infect. Dis."},{"key":"580_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-95","volume":"13","author":"I Gonzalez-Suarez","year":"2013","unstructured":"Gonzalez-Suarez, I., Sanz-Gallego, I., Rodriguez de Rivera, F. J. & Arpa, J. Guillain-Barre syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol. 13, 95 (2013).","journal-title":"BMC Neurol."},{"key":"580_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/WNL.0b013e3181cff735","volume":"74","author":"Z Islam","year":"2010","unstructured":"Islam, Z. et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 74, 581\u2013587 (2010).","journal-title":"Neurology"},{"key":"580_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jns.12215","volume":"22","author":"T Ishaque","year":"2017","unstructured":"Ishaque, T. et al. High mortality from Guillain-Barre syndrome in Bangladesh. J. Peripher. Nerv. Syst. 22, 121\u2013126 (2017).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR24","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","volume":"80","author":"B van den Berg","year":"2013","unstructured":"van den Berg, B., Bunschoten, C., van Doorn, P. A. & Jacobs, B. C. Mortality in Guillain-Barr\u00e9 syndrome. Neurology 80, 1650\u20131654 (2013).","journal-title":"Neurology"},{"key":"580_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/cid\/cir074","volume":"52","author":"D Orlikowski","year":"2011","unstructured":"Orlikowski, D. et al. Guillain-Barre syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin. Infect. Dis. 52, 837\u2013844 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"580_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","volume":"82","author":"B van den Berg","year":"2014","unstructured":"van den Berg, B. et al. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology 82, 491\u2013497 (2014).","journal-title":"Neurology"},{"key":"580_CR27","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s00415-011-6042-9","volume":"258","author":"C Caudie","year":"2011","unstructured":"Caudie, C. et al. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barre syndrome patients. J. Neurol. 258, 1958\u20131964 (2011).","journal-title":"J. Neurol."},{"key":"580_CR28","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000200885","volume":"99","author":"SE Leonhard","year":"2022","unstructured":"Leonhard, S. E. et al. An international perspective on preceding infections in guillain-barre syndrome: the IGOS-1000 cohort. Neurology 99, e1299\u2013e1313 (2022). A description of serological evidence of preceding infections in patients with GBS in a large international cohort study.","journal-title":"Neurology"},{"key":"580_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0022-510X(02)00418-5","volume":"208","author":"TH Brannagan 3rd","year":"2003","unstructured":"Brannagan, T. H. 3rd & Zhou, Y. HIV-associated Guillain-Barre syndrome. J. Neurol. Sci. 208, 39\u201342 (2003).","journal-title":"J. Neurol. Sci."},{"key":"580_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/jns.12190","volume":"21","author":"T Umapathi","year":"2016","unstructured":"Umapathi, T. et al. Asymptomatic dengue infection may trigger Guillain-Barre syndrome. J. Peripher. Nerv. Syst. 21, 375\u2013377 (2016).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jns.2017.02.024","volume":"375","author":"FL Hiew","year":"2017","unstructured":"Hiew, F. L. & Rajabally, Y. A. Malignancy in Guillain-Barre syndrome: a twelve-year single-center study. J. Neurol. Sci. 375, 275\u2013278 (2017).","journal-title":"J. Neurol. Sci."},{"key":"580_CR32","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1016\/j.vaccine.2018.05.119","volume":"37","author":"N Principi","year":"2019","unstructured":"Principi, N. & Esposito, S. Vaccine-preventable diseases, vaccines and Guillain-Barre\u2019 syndrome. Vaccine 37, 5544\u20135550 (2019). A comprehensive review on the relation between vaccines and GBS.","journal-title":"Vaccine"},{"key":"580_CR33","doi-asserted-by":"publisher","first-page":"e1220","DOI":"10.1212\/WNL.0000000000006246","volume":"91","author":"J Rudant","year":"2018","unstructured":"Rudant, J. et al. Surgery and risk of Guillain-Barre syndrome: a French nationwide epidemiologic study. Neurology 91, e1220\u2013e1227 (2018).","journal-title":"Neurology"},{"key":"580_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10096-018-3199-5","volume":"37","author":"B Islam","year":"2018","unstructured":"Islam, B. et al. Guillain-Barre syndrome following varicella-zoster virus infection. Eur. J. Clin. Microbiol. Infect. Dis. 37, 511\u2013518 (2018).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"580_CR35","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao, J. C. et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 74, 1216\u20131222 (2017).","journal-title":"JAMA Neurol."},{"key":"580_CR36","doi-asserted-by":"publisher","first-page":"e1555","DOI":"10.1212\/WNL.0000000000200015","volume":"98","author":"LS Levison","year":"2022","unstructured":"Levison, L. S., Thomsen, R. W., Sindrup, S. H. & Andersen, H. Association between incident cancer and Guillain-Barr\u00e9 syndrome development: a nationwide case-control study. Neurology 98, e1555\u2013e1561 (2022).","journal-title":"Neurology"},{"key":"580_CR37","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1017\/S0950268813001908","volume":"142","author":"BR Jackson","year":"2014","unstructured":"Jackson, B. R. et al. Binational outbreak of Guillain-Barre syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011. Epidemiol. Infect. 142, 1089\u20131099 (2014).","journal-title":"Epidemiol. Infect."},{"key":"580_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1089\/fpd.2009.0493","volume":"7","author":"M Zhang","year":"2010","unstructured":"Zhang, M. et al. Association study between an outbreak of Guillain-Barre syndrome in Jilin, China, and preceding Campylobacter jejuni infection. Foodborne Pathog. Dis. 7, 913\u2013919 (2010).","journal-title":"Foodborne Pathog. Dis."},{"key":"580_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ensci.2019.02.001","volume":"14","author":"S Diaz-Soto","year":"2019","unstructured":"Diaz-Soto, S., Chavez, K., Chaca, A., Alanya, J. & Tirado-Hurtado, I. Outbreak of Guillain-Barre syndrome in Peru. eNeurologicalSci 14, 89\u201390 (2019).","journal-title":"eNeurologicalSci"},{"key":"580_CR40","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000952","volume":"8","author":"AP Ramos","year":"2021","unstructured":"Ramos, A. P. et al. Guillain-Barre syndrome outbreak in Peru 2019 associated with Campylobacter jejuni infection. Neurol. Neuroimmunol. Neuroinflamm. 8, e952 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"580_CR41","unstructured":"Disease outbreak news. Guillain-Barr\u00e9 syndrome in Peru. World Health Organization https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON477 (2023)."},{"key":"580_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/504294","volume":"194","author":"CC Tam","year":"2006","unstructured":"Tam, C. C. et al. Incidence of Guillain-Barr\u00e9 Syndrome among patients with campylobacter infection: a general practice research database study. J. Infect. Dis. 194, 95\u201397 (2006).","journal-title":"J. Infect. Dis."},{"key":"580_CR43","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/aje\/153.6.610","volume":"153","author":"N McCarthy","year":"2001","unstructured":"McCarthy, N. & Giesecke, J. Incidence of Guillain-Barr\u00e9 Syndrome following Infection with Campylobacter jejuni. Am. J. Epidemiol. 153, 610\u2013614 (2001).","journal-title":"Am. J. Epidemiol."},{"key":"580_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000344","volume":"2","author":"CC Tam","year":"2007","unstructured":"Tam, C. C. et al. Guillain-Barr\u00e9 syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS ONE\u00a02, e344 (2007).","journal-title":"PLoS ONE"},{"key":"580_CR45","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/aje\/kwn310","volume":"169","author":"J Stowe","year":"2009","unstructured":"Stowe, J., Andrews, N., Wise, L. & Miller, E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol. 169, 382\u2013388 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"580_CR46","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(11)61665-6","volume":"378","author":"C Verity","year":"2011","unstructured":"Verity, C. et al. Guillain-Barr\u00e9 syndrome and H1N1 influenza vaccine in UK children. Lancet 378, 1545\u20131546 (2011).","journal-title":"Lancet"},{"key":"580_CR47","unstructured":"Zika situation report, March 10. World Health Organization https:\/\/iris.who.int\/bitstream\/handle\/10665\/251001\/zikasitrep10Nov16-eng.pdf (2016)."},{"key":"580_CR48","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","volume":"387","author":"VM Cao-Lormeau","year":"2016","unstructured":"Cao-Lormeau, V. M. et al. Guillain-Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531\u20131539 (2016).","journal-title":"Lancet"},{"key":"580_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008264","volume":"14","author":"SE Leonhard","year":"2020","unstructured":"Leonhard, S. E. et al. Guillain-Barre syndrome related to Zika virus infection: a systematic review and meta-analysis of the clinical and electrophysiological phenotype. PLoS Negl. Trop. Dis. 14, e0008264 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"580_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1052-4","volume":"16","author":"YT-RL Mier","year":"2018","unstructured":"Mier, Y. T.-R. L., Delorey, M. J., Sejvar, J. J. & Johansson, M. A. Guillain-Barr\u00e9 syndrome risk among individuals infected with Zika virus: a multi-country assessment. BMC Med. 16, 67 (2018).","journal-title":"BMC Med."},{"key":"580_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008032","volume":"14","author":"I Grijalva","year":"2020","unstructured":"Grijalva, I. et al. Zika and dengue but not chikungunya are associated with Guillain-Barr\u00e9 syndrome in Mexico: a case-control study. PLoS Negl. Trop. Dis. 14, e0008032 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"580_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz625","author":"S Stegmann-Planchard","year":"2019","unstructured":"Stegmann-Planchard, S. et al. Chikungunya, a risk factor for Guillain-Barr\u00e9 syndrome. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciz625 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"580_CR53","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S1474-4422(20)30232-5","volume":"19","author":"ML Brito Ferreira","year":"2020","unstructured":"Brito Ferreira, M. L. et al. Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. Lancet Neurol. 19, 826\u2013839 (2020).","journal-title":"Lancet Neurol."},{"key":"580_CR54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/jnnp-2020-324837","volume":"92","author":"M Filosto","year":"2020","unstructured":"Filosto, M. et al. Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J. Neurol. Neurosurg. Psychiatry 92, 751\u2013756 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR55","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ana.25987","volume":"89","author":"M Fragiel","year":"2020","unstructured":"Fragiel, M. et al. Incidence, clinical, risk factors and outcomes of Guillain-Barre in Covid-19. Ann. Neurol. 89, 598\u2013603 (2020).","journal-title":"Ann. Neurol."},{"key":"580_CR56","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone, M. et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat. Med. 27, 2144\u20132153 (2021).","journal-title":"Nat. Med."},{"key":"580_CR57","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/brain\/awaa444","volume":"144","author":"MP Lunn","year":"2021","unstructured":"Lunn, M. P. et al. COVID-19 vaccine and Guillain-Barre syndrome: let\u2019s not leap to associations. Brain 144, 357\u2013360 (2021).","journal-title":"Brain"},{"key":"580_CR58","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/brain\/awaa433","volume":"144","author":"S Keddie","year":"2021","unstructured":"Keddie, S. et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. Brain 144, 682\u2013693 (2021).","journal-title":"Brain"},{"key":"580_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16439","volume":"31","author":"M Blanco-Ruiz","year":"2024","unstructured":"Blanco-Ruiz, M. et al. A nationwide Guillain-Barr\u00e9 syndrome epidemiological study in Spain during the COVID-19 years. Eur. J. Neurol. 31, e16439 (2024).","journal-title":"Eur. J. Neurol."},{"key":"580_CR60","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/brain\/awab279","volume":"144","author":"LWG Luijten","year":"2021","unstructured":"Luijten, L. W. G. et al. Guillain-Barr\u00e9 syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain 144, 3392\u20133404 (2021).","journal-title":"Brain"},{"key":"580_CR61","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger, L. B. et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am. J. Epidemiol. 110, 105\u2013123 (1979).","journal-title":"Am. J. Epidemiol."},{"key":"580_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10654-015-0047-0","volume":"31","author":"S Ghaderi","year":"2016","unstructured":"Ghaderi, S. et al. Risk of Guillain-Barre syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study. Eur. J. Epidemiol. 31, 67\u201372 (2016).","journal-title":"Eur. J. Epidemiol."},{"key":"580_CR63","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","volume":"104","author":"C Vellozzi","year":"2014","unstructured":"Vellozzi, C., Iqbal, S., Stewart, B., Tokars, J. & DeStefano, F. Cumulative risk of Guillain\u2013Barr\u00e9 syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic. Am. J. Public Health 104, 696\u2013701 (2014).","journal-title":"Am. J. Public Health"},{"key":"580_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamaneurol.2023.5208","volume":"81","author":"AG Willison","year":"2024","unstructured":"Willison, A. G. et al. SARS-CoV-2 vaccination and neuroimmunological disease: a review. JAMA Neurol. 81, 179\u2013186 (2024). A review summarizing the evidence of a possible association between SARS-CoV-2 infection, SARS-CoV-2 vaccines and GBS.","journal-title":"JAMA Neurol."},{"key":"580_CR65","doi-asserted-by":"publisher","first-page":"e2035","DOI":"10.1212\/WNL.0000000000207900","volume":"101","author":"H Bishara","year":"2023","unstructured":"Bishara, H. et al. Association between Guillain-Barr\u00e9 syndrome and COVID-19 infection and vaccination: a population-based nested case-control study. Neurology 101, e2035\u2013e2042 (2023).","journal-title":"Neurology"},{"key":"580_CR66","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jneuroim.2006.07.017","volume":"180","author":"PA McCombe","year":"2006","unstructured":"McCombe, P. A., Csurhes, P. A. & Greer, J. M. Studies of HLA associations in male and female patients with Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J. Neuroimmunol. 180, 172\u2013177 (2006).","journal-title":"J. Neuroimmunol."},{"key":"580_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1212\/01.WNL.0000148727.02732.01","volume":"64","author":"K Geleijns","year":"2005","unstructured":"Geleijns, K. et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. Neurology 64, 44\u201349 (2005).","journal-title":"Neurology"},{"key":"580_CR68","first-page":"CD001446","volume":"10","author":"RA Hughes","year":"2012","unstructured":"Hughes, R. A. & van Doorn, P. A. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst. Rev. 10, CD001446 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"580_CR69","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"RD Hadden","year":"1998","unstructured":"Hadden, R. D. et al. Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group. Ann. Neurol. 44, 780\u2013788 (1998).","journal-title":"Ann. Neurol."},{"key":"580_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jns.12532","volume":"28","author":"ME Cunningham","year":"2023","unstructured":"Cunningham, M. E. et al. Axolemmal nanoruptures arising from paranodal membrane injury induce secondary axon degeneration in murine Guillain-Barre syndrome. J. Peripher. Nerv. Syst. 28, 17\u201331 (2023).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00005792-194902010-00003","volume":"28","author":"WE Haymaker","year":"1949","unstructured":"Haymaker, W. E. & Kernohan, J. W. The Landry-Guillain-Barre syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine 28, 59\u2013141 (1949). A seminal study on the histopathology of GBS.","journal-title":"Medicine"},{"key":"580_CR72","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/brain\/awg207","volume":"126","author":"J Wanschitz","year":"2003","unstructured":"Wanschitz, J., Maier, H., Lassmann, H., Budka, H. & Berger, T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain 126, 2034\u20132042 (2003).","journal-title":"Brain"},{"key":"580_CR73","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ana.410090713","volume":"9","author":"H Nyland","year":"1981","unstructured":"Nyland, H., Matre, R. & Mork, S. Immunological characterization of sural nerve biopsies from patients with Guillain-Barre syndrome. Ann. Neurol. 9, 80\u201386 (1981).","journal-title":"Ann. Neurol."},{"key":"580_CR74","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jca.2920020417","volume":"2","author":"R Addison","year":"1985","unstructured":"Addison, R. et al. Plasma exchange in acute Guillain-Barre\u2019 syndrome. J. Clin. Apher. 2, 321\u2013325 (1985).","journal-title":"J. Clin. Apher."},{"key":"580_CR75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ana.410230503","volume":"23","author":"AA Ilyas","year":"1988","unstructured":"Ilyas, A. A. et al. Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann. Neurol. 23, 440\u2013447 (1988).","journal-title":"Ann. Neurol."},{"key":"580_CR76","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"HJ Willison","year":"2002","unstructured":"Willison, H. J. & Yuki, N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125, 2591\u20132625 (2002). An extensive review on the role of anti-glycolipid antibodies in the pathogenesis of GBS and adjacent peripheral neuropathies.","journal-title":"Brain"},{"key":"580_CR77","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4939-8552-4_7","volume":"1804","author":"HJ Willison","year":"2018","unstructured":"Willison, H. J. Anti-ganglioside antibodies in peripheral nerve pathology. Methods Mol. Biol. 1804, 173\u2013188 (2018).","journal-title":"Methods Mol. Biol."},{"key":"580_CR78","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.24442","volume":"78","author":"R Huizinga","year":"2015","unstructured":"Huizinga, R. et al. Innate immunity to Campylobacter jejuni in Guillain-Barre syndrome. Ann. Neurol. 78, 343\u2013354 (2015).","journal-title":"Ann. Neurol."},{"key":"580_CR79","doi-asserted-by":"publisher","first-page":"19611","DOI":"10.1021\/jacs.0c08583","volume":"142","author":"T Li","year":"2020","unstructured":"Li, T. et al. Chemoenzymatic synthesis of Campylobacter jejuni lipo-oligosaccharide core domains to examine Guillain-Barre syndrome serum antibody specificities. J. Am. Chem. Soc. 142, 19611\u201319621 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"580_CR80","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jneuroim.2006.10.015","volume":"182","author":"NM van Sorge","year":"2007","unstructured":"van Sorge, N. M. et al. Ganglioside-specific IgG and IgA recruit leukocyte effector functions in Guillain\u2013Barr\u00e9 syndrome. J. Neuroimmunol. 182, 177\u2013184 (2007).","journal-title":"J. Neuroimmunol."},{"key":"580_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02301-0","volume":"18","author":"C Lleix\u00e0","year":"2021","unstructured":"Lleix\u00e0, C. et al. Autoantibody screening in Guillain\u2013Barr\u00e9 syndrome. J. Neuroinflamm. 18, 251 (2021).","journal-title":"J. Neuroinflamm."},{"key":"580_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200107","volume":"10","author":"RCM Thomma","year":"2023","unstructured":"Thomma, R. C. M. et al. High and persistent Anti-GM1 antibody titers are associated with poor clinical recovery in Guillain-Barr\u00e9 syndrome. Neurol. Neuroimmunol. Neuroinflamm. 10, e200107 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"580_CR83","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/01.wnl.0000335160.72184.7d","volume":"71","author":"K Kaida","year":"2008","unstructured":"Kaida, K. et al. GM1\/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome. Neurology 71, 1683\u20131690 (2008).","journal-title":"Neurology"},{"key":"580_CR84","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1471-4159.2007.04707.x","volume":"103","author":"N Yuki","year":"2007","unstructured":"Yuki, N. Campylobacter sialyltransferase gene polymorphism directs clinical features of Guillain-Barre syndrome. J. Neurochem. 103, 150\u2013158 (2007).","journal-title":"J. Neurochem."},{"key":"580_CR85","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/brain\/124.5.893","volume":"124","author":"GM O\u2019Hanlon","year":"2001","unstructured":"O\u2019Hanlon, G. M. et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124, 893\u2013906 (2001).","journal-title":"Brain"},{"key":"580_CR86","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/brain\/awq119","volume":"133","author":"R McGonigal","year":"2010","unstructured":"McGonigal, R. et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 133, 1944\u20131960 (2010).","journal-title":"Brain"},{"key":"580_CR87","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1172\/JCI37338","volume":"119","author":"KN Greenshields","year":"2009","unstructured":"Greenshields, K. N. et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J. Clin. Invest. 119, 595\u2013610 (2009).","journal-title":"J. Clin. Invest."},{"key":"580_CR88","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI59110","volume":"122","author":"SN Fewou","year":"2012","unstructured":"Fewou, S. N. et al. Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J. Clin. Invest. 122, 1037\u20131051 (2012).","journal-title":"J. Clin. Invest."},{"key":"580_CR89","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/brain\/aww056","volume":"139","author":"ME Cunningham","year":"2016","unstructured":"Cunningham, M. E. et al. Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis. Brain 139, 1657\u20131665 (2016).","journal-title":"Brain"},{"key":"580_CR90","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0140-6736(94)92694-8","volume":"343","author":"M Roberts","year":"1994","unstructured":"Roberts, M., Willison, H., Vincent, A. & Newsom-Davis, J. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 343, 454\u2013455 (1994).","journal-title":"Lancet"},{"key":"580_CR91","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/1531-8249(199902)45:2<189::AID-ANA9>3.0.CO;2-T","volume":"45","author":"JJ Plomp","year":"1999","unstructured":"Plomp, J. J. et al. Miller Fisher anti-GQ1b antibodies: \u03b1-latrotoxin-like effects on motor end plates. Ann. Neurol. 45, 189\u2013199 (1999).","journal-title":"Ann. Neurol."},{"key":"580_CR92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158524","volume":"132","author":"R McGonigal","year":"2022","unstructured":"McGonigal, R. et al. Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barre syndrome mouse model. J. Clin. Invest. 132, e158524 (2022).","journal-title":"J. Clin. Invest."},{"key":"580_CR93","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.nrl.2018.06.002","volume":"37","author":"J Berciano","year":"2022","unstructured":"Berciano, J. Axonal pathology in early stages of Guillain-Barre syndrome. Neurologia 37, 466\u2013479 (2022). An opinion paper on the role of early inflammatory oedema of proximal nerve trunks in the pathogenesis of GBS.","journal-title":"Neurologia"},{"key":"580_CR94","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jneuroim.2007.09.034","volume":"192","author":"LJ Chi","year":"2007","unstructured":"Chi, L. J., Wang, H. B., Zhang, Y. & Wang, W. Z. Abnormality of circulating CD4+CD25+ regulatory T cell in patients with Guillain-Barre syndrome. J. Neuroimmunol. 192, 206\u2013214 (2007).","journal-title":"J. Neuroimmunol."},{"key":"580_CR95","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/mus.880170510","volume":"17","author":"JR Wilson","year":"1994","unstructured":"Wilson, J. R., Conwit, R. A., Eidelman, B. H., Starzl, T. & Abu-Elmagd, K. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 17, 528\u2013532 (1994).","journal-title":"Muscle Nerve"},{"key":"580_CR96","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","volume":"8","author":"M Hamadani","year":"2021","unstructured":"Hamadani, M. et al. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 8, e433\u2013e445 (2021).","journal-title":"Lancet Haematol."},{"key":"580_CR97","doi-asserted-by":"publisher","first-page":"120089","DOI":"10.1016\/j.jns.2021.120089","volume":"432","author":"E Khan","year":"2022","unstructured":"Khan, E. et al. CNS and PNS manifestation in immune checkpoint inhibitors: a systematic review. J. Neurol. Sci. 432, 120089 (2022).","journal-title":"J. Neurol. Sci."},{"key":"580_CR98","doi-asserted-by":"publisher","first-page":"3390831","DOI":"10.1155\/2022\/3390831","volume":"2022","author":"S Sarejloo","year":"2022","unstructured":"Sarejloo, S. et al. Role of the neutrophil to lymphocyte ratio in Guillain Barre syndrome: a systematic review and meta-analysis. Mediators Inflamm. 2022, 3390831 (2022).","journal-title":"Mediators Inflamm."},{"key":"580_CR99","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.3892\/mmr.2015.3730","volume":"12","author":"Y Du","year":"2015","unstructured":"Du, Y. et al. Toll-like receptor 2 and -4 are involved in the pathogenesis of the Guillain-Barre syndrome. Mol. Med. Rep. 12, 3207\u20133213 (2015).","journal-title":"Mol. Med. Rep."},{"key":"580_CR100","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/acn3.744","volume":"6","author":"I Jahan","year":"2019","unstructured":"Jahan, I. et al. Toll-like receptor-4 299Gly allele is associated with Guillain-Barre syndrome in Bangladesh. Ann. Clin. Transl. Neurol. 6, 708\u2013715 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"580_CR101","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/brain\/118.4.869","volume":"118","author":"EJ Redford","year":"1995","unstructured":"Redford, E. J., Hall, S. M. & Smith, K. J. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 118, 869\u2013878 (1995).","journal-title":"Brain"},{"key":"580_CR102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410390105","volume":"39","author":"JW Griffin","year":"1996","unstructured":"Griffin, J. W. et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann. Neurol. 39, 17\u201328 (1996).","journal-title":"Ann. Neurol."},{"key":"580_CR103","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fnins.2019.00717","volume":"13","author":"T Sun","year":"2019","unstructured":"Sun, T., Chen, X., Shi, S., Liu, Q. & Cheng, Y. Peripheral blood and cerebrospinal fluid cytokine levels in Guillain Barre syndrome: a systematic review and meta-analysis. Front. Neurosci. 13, 717 (2019).","journal-title":"Front. Neurosci."},{"key":"580_CR104","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jneuroim.2017.10.003","volume":"313","author":"J Liu","year":"2017","unstructured":"Liu, J. et al. Associations between tumor necrosis factor-alpha gene polymorphisms and the risk of Guillain-Barre syndrome and its subtypes: a systematic review and meta-analysis. J. Neuroimmunol. 313, 25\u201333 (2017).","journal-title":"J. Neuroimmunol."},{"key":"580_CR105","doi-asserted-by":"publisher","first-page":"bcr2017219481","DOI":"10.1136\/bcr-2017-219481","volume":"2017","author":"K Patwala","year":"2017","unstructured":"Patwala, K., Crump, N. & De Cruz, P. Guillain-Barre syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity. BMJ Case Rep. 2017, bcr2017219481 (2017).","journal-title":"BMJ Case Rep."},{"key":"580_CR106","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jneuroim.2018.08.001","volume":"323","author":"M Debnath","year":"2018","unstructured":"Debnath, M. et al. Th17 pathway signatures in a large Indian cohort of Guillain Barr\u00e9 syndrome. J. Neuroimmunol. 323, 125\u2013130 (2018).","journal-title":"J. Neuroimmunol."},{"key":"580_CR107","doi-asserted-by":"publisher","first-page":"740947","DOI":"10.1155\/2014\/740947","volume":"2014","author":"S Li","year":"2014","unstructured":"Li, S. et al. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barr\u00e9 syndrome and downregulated by IVIg treatments. Mediators Inflamm. 2014, 740947 (2014).","journal-title":"Mediators Inflamm."},{"key":"580_CR108","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jocn.2020.03.010","volume":"75","author":"M Debnath","year":"2020","unstructured":"Debnath, M. et al. Evidence of altered Th17 pathway signatures in the cerebrospinal fluid of patients with Guillain Barr\u00e9 Syndrome. J. Clin. Neurosci. 75, 176\u2013180 (2020).","journal-title":"J. Clin. Neurosci."},{"key":"580_CR109","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-010-5836-5","volume":"258","author":"MO Lu","year":"2011","unstructured":"Lu, M. O. & Zhu, J. The role of cytokines in Guillain-Barr\u00e9 syndrome. J. Neurol. 258, 533\u2013548 (2011).","journal-title":"J. Neurol."},{"key":"580_CR110","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9","volume":"19","author":"B Schmidt","year":"1996","unstructured":"Schmidt, B. et al. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19, 474\u2013487 (1996).","journal-title":"Muscle Nerve"},{"key":"580_CR111","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06916-6","volume":"626","author":"L S\u00faken\u00edkov\u00e1","year":"2024","unstructured":"S\u00faken\u00edkov\u00e1, L. et al. Autoreactive T cells target peripheral nerves in Guillain\u2013Barr\u00e9 syndrome. Nature 626, 160\u2013168 (2024).","journal-title":"Nature"},{"key":"580_CR112","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.4049\/jimmunol.155.6.3049","volume":"155","author":"G Paterson","year":"1995","unstructured":"Paterson, G., Wilson, G., Kennedy, P. G. & Willison, H. J. Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropathy patients demonstrates diverse V region gene usage with extensive somatic mutation. J. Immunol. 155, 3049\u20133059 (1995).","journal-title":"J. Immunol."},{"key":"580_CR113","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1084\/jem.102.2.213","volume":"102","author":"BH Waksman","year":"1955","unstructured":"Waksman, B. H. & Adams, R. D. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J. Exp. Med. 102, 213\u2013236 (1955).","journal-title":"J. Exp. Med."},{"key":"580_CR114","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ana.1012","volume":"49","author":"N Yuki","year":"2001","unstructured":"Yuki, N. et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 49, 712\u2013720 (2001).","journal-title":"Ann. Neurol."},{"key":"580_CR115","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awm316","volume":"131","author":"SK Halstead","year":"2008","unstructured":"Halstead, S. K. et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131, 1197\u20131208 (2008).","journal-title":"Brain"},{"key":"580_CR116","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0022-510X(00)00287-2","volume":"175","author":"M Odaka","year":"2000","unstructured":"Odaka, M., Yuki, N., Nobile-Orazio, E., Carpo, M. & Hirata, K. Antibodies to GM1(NeuGc) in Guillain-Barre syndrome after ganglioside therapy. J. Neurol. Sci. 175, 96\u2013106 (2000).","journal-title":"J. Neurol. Sci."},{"key":"580_CR117","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/brain\/120.7.1123","volume":"120","author":"V Govoni","year":"1997","unstructured":"Govoni, V. et al. Exogenous gangliosides and Guillain-Barre syndrome. An observational study in the local health district of Ferrara, Italy. Brain 120, 1123\u20131130 (1997).","journal-title":"Brain"},{"key":"580_CR118","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/0008-8749(85)90233-3","volume":"91","author":"A Rostami","year":"1985","unstructured":"Rostami, A. et al. Transfer of experimental allergic neuritis with P2-reactive T-cell lines. Cell Immunol. 91, 354\u2013361 (1985).","journal-title":"Cell Immunol."},{"key":"580_CR119","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/ana.410190109","volume":"19","author":"K Heininger","year":"1986","unstructured":"Heininger, K., Stoll, G., Linington, C., Toyka, K. V. & Wekerle, H. Conduction failure and nerve conduction slowing in experimental allergic neuritis induced by P2-specific T-cell lines. Ann. Neurol. 19, 44\u201349 (1986).","journal-title":"Ann. Neurol."},{"key":"580_CR120","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0022-510X(93)90174-W","volume":"117","author":"JJ Archelos","year":"1993","unstructured":"Archelos, J. J., Roggenbuck, K., Schneider-Schaulies, J., Toyka, K. V. & Hartung, H. P. Detection and quantification of antibodies to the extracellular domain of P0 during experimental allergic neuritis. J. Neurol. Sci. 117, 197\u2013205 (1993).","journal-title":"J. Neurol. Sci."},{"key":"580_CR121","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/mus.880161106","volume":"16","author":"AF Hahn","year":"1993","unstructured":"Hahn, A. F., Feasby, T. E., Wilkie, L. & Lovgren, D. Antigalactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis. Muscle Nerve 16, 1174\u20131180 (1993).","journal-title":"Muscle Nerve"},{"key":"580_CR122","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1128\/IAI.70.9.5008-5018.2002","volume":"70","author":"T Bowes","year":"2002","unstructured":"Bowes, T. et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect. Immun. 70, 5008\u20135018 (2002).","journal-title":"Infect. Immun."},{"key":"580_CR123","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1523\/JNEUROSCI.4017-06.2007","volume":"27","author":"HC Lehmann","year":"2007","unstructured":"Lehmann, H. C. et al. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J. Neurosci. 27, 27\u201334 (2007).","journal-title":"J. Neurosci."},{"key":"580_CR124","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila, N., Lehmann, H. C. & Kuwabara, S. Guillain-Barre syndrome. Lancet 397, 1214\u20131228 (2021).","journal-title":"Lancet"},{"key":"580_CR125","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/jnnp-2012-302824","volume":"84","author":"N Shahrizaila","year":"2013","unstructured":"Shahrizaila, N. & Yuki, N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J. Neurol. Neurosurg. Psychiatry 84, 576\u2013583 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR126","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","volume":"10","author":"BR Wakerley","year":"2014","unstructured":"Wakerley, B. R., Uncini, A., Yuki, N., GBS Classification Group. Guillain-Barre and Miller Fisher syndromes-new diagnostic classification. Nat. Rev. Neurol. 10, 537\u2013544 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"580_CR127","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","volume":"27","author":"AK Asbury","year":"1990","unstructured":"Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann. Neurol. 27, S21\u2013S24 (1990).","journal-title":"Ann. Neurol."},{"key":"580_CR128","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","volume":"29","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar, J. J. et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29, 599\u2013612 (2011).","journal-title":"Vaccine"},{"key":"580_CR129","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard, S. E. et al. Diagnosis and management of Guillain-Barre syndrome in ten steps. Nat. Rev. Neurol. 15, 671\u2013683 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"580_CR130","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","volume":"137","author":"C Fokke","year":"2014","unstructured":"Fokke, C. et al. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain 137, 33\u201343 (2014).","journal-title":"Brain"},{"key":"580_CR131","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","volume":"74","author":"L Ruts","year":"2010","unstructured":"Ruts, L., Drenthen, J., Jacobs, B. C., van Doorn, P. A. & Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 74, 1680\u20131686 (2010).","journal-title":"Neurology"},{"key":"580_CR132","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1212\/WNL.0b013e31820e7b62","volume":"76","author":"J Roodbol","year":"2011","unstructured":"Roodbol, J. et al. Recognizing Guillain-Barre syndrome in preschool children. Neurology 76, 807\u2013810 (2011).","journal-title":"Neurology"},{"key":"580_CR133","doi-asserted-by":"publisher","first-page":"e2386","DOI":"10.1212\/WNL.0000000000207282","volume":"100","author":"H Al-Hakem","year":"2023","unstructured":"Al-Hakem, H. et al. CSF findings in relation to clinical characteristics, subtype, and disease course in patients with Guillain-Barre syndrome. Neurology 100, e2386\u2013e2397 (2023).","journal-title":"Neurology"},{"key":"580_CR134","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/archneur.58.6.913","volume":"58","author":"PH Gordon","year":"2001","unstructured":"Gordon, P. H. & Wilbourn, A. J. Early electrodiagnostic findings in Guillain-Barre syndrome. Arch. Neurol. 58, 913\u2013917 (2001).","journal-title":"Arch. Neurol."},{"key":"580_CR135","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.clinph.2004.05.009","volume":"115","author":"S Vucic","year":"2004","unstructured":"Vucic, S., Cairns, K. D., Black, K. R., Chong, P. S. & Cros, D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin. Neurophysiol. 115, 2329\u20132335 (2004).","journal-title":"Clin. Neurophysiol."},{"key":"580_CR136","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.clinph.2015.01.016","volume":"126","author":"T Umapathi","year":"2015","unstructured":"Umapathi, T., Li, Z., Verma, K. & Yuki, N. Sural-sparing is seen in axonal as well as demyelinating forms of Guillain-Barre syndrome. Clin. Neurophysiol. 126, 2376\u20132380 (2015).","journal-title":"Clin. Neurophysiol."},{"key":"580_CR137","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/jnnp-2014-307815","volume":"86","author":"YA Rajabally","year":"2015","unstructured":"Rajabally, Y. A., Durand, M. C., Mitchell, J., Orlikowski, D. & Nicolas, G. Electrophysiological diagnosis of Guillain-Barre syndrome subtype: could a single study suffice? J. Neurol. Neurosurg. Psychiatry 86, 115\u2013119 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR138","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ana.410310619","volume":"31","author":"A Chiba","year":"1992","unstructured":"Chiba, A., Kusunoki, S., Shimizu, T. & Kanazawa, I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 31, 677\u2013679 (1992).","journal-title":"Ann. Neurol."},{"key":"580_CR139","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1212\/WNL.43.10.1911","volume":"43","author":"A Chiba","year":"1993","unstructured":"Chiba, A., Kusunoki, S., Obata, H., Machinami, R. & Kanazawa, I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 43, 1911\u20131917 (1993).","journal-title":"Neurology"},{"key":"580_CR140","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh, P. Y. K. et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J. Peripher. Nerv. Syst. 26, 242\u2013268 (2021).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR141","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.56.6.758","volume":"56","author":"RD Hadden","year":"2001","unstructured":"Hadden, R. D. et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 56, 758\u2013765 (2001).","journal-title":"Neurology"},{"key":"580_CR142","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.clinph.2014.06.051","volume":"126","author":"E Gallardo","year":"2015","unstructured":"Gallardo, E. et al. Spinal nerve involvement in early Guillain-Barre syndrome: a clinico-electrophysiological, ultrasonographic and pathological study. Clin. Neurophysiol. 126, 810\u2013819 (2015).","journal-title":"Clin. Neurophysiol."},{"key":"580_CR143","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.clinph.2015.06.030","volume":"127","author":"SNO Razali","year":"2016","unstructured":"Razali, S. N. O. et al. Serial peripheral nerve ultrasound in Guillain-Barre syndrome. Clin. Neurophysiol. 127, 1652\u20131656 (2016).","journal-title":"Clin. Neurophysiol."},{"key":"580_CR144","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13311-019-00716-5","volume":"16","author":"A Grimm","year":"2019","unstructured":"Grimm, A. et al. Differentiation between Guillain\u2013Barr\u00e9 Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis \u2014 a prospective follow-up study using ultrasound and neurophysiological measurements. Neurotherapeutics 16, 838\u2013847 (2019).","journal-title":"Neurotherapeutics"},{"key":"580_CR145","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3201\/eid1802.111126","volume":"18","author":"MG Baker","year":"2012","unstructured":"Baker, M. G. et al. Declining Guillain-Barre syndrome after campylobacteriosis control, New Zealand, 1988-2010. Emerg. Infect. Dis. 18, 226\u2013233 (2012).","journal-title":"Emerg. Infect. Dis."},{"key":"580_CR146","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K. et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann. Neurol. 66, 597\u2013603 (2009).","journal-title":"Ann. Neurol."},{"key":"580_CR147","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40262-022-01136-z","volume":"61","author":"WJR Fokkink","year":"2022","unstructured":"Fokkink, W. J. R. et al. Population pharmacokinetic modelling of intravenous immunoglobulin treatment in patients with Guillain-Barre syndrome. Clin. Pharmacokinet. 61, 1285\u20131296 (2022).","journal-title":"Clin. Pharmacokinet."},{"key":"580_CR148","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ana.410230407","volume":"23","author":"DR Cornblath","year":"1988","unstructured":"Cornblath, D. R. et al. Motor conduction studies in Guillain-Barre syndrome: description and prognostic value. Ann. Neurol. 23, 354\u2013359 (1988).","journal-title":"Ann. Neurol."},{"key":"580_CR149","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1212\/WNL.48.1.214","volume":"48","author":"Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology.","year":"1997","unstructured":"Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. A prospective study on the incidence and prognosis of Guillain-Barre syndrome in Emilia-Romagna region, Italy (1992-1993). Neurology 48, 214\u2013221 (1997).","journal-title":"Neurology"},{"key":"580_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09621-y","volume":"12","author":"I Jahan","year":"2022","unstructured":"Jahan, I. et al. Association of mannose-binding lectin 2 gene polymorphisms with Guillain-Barr\u00e9 syndrome. Sci. Rep. 12, 5791 (2022).","journal-title":"Sci. Rep."},{"key":"580_CR151","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.4049\/jimmunol.177.6.4211","volume":"177","author":"K Geleijns","year":"2006","unstructured":"Geleijns, K. et al. Mannose-binding lectin contributes to the severity of Guillain-Barre syndrome. J. Immunol. 177, 4211\u20134217 (2006).","journal-title":"J. Immunol."},{"key":"580_CR152","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp-2020-323899","volume":"92","author":"L Mart\u00edn-Aguilar","year":"2021","unstructured":"Mart\u00edn-Aguilar, L. et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr\u00e9 syndrome patients. J. Neurol. Neurosurg. Psychiatry 92, 70\u201377 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR153","doi-asserted-by":"publisher","first-page":"105072","DOI":"10.1016\/j.ebiom.2024.105072","volume":"102","author":"SJ van Tilburg","year":"2024","unstructured":"van Tilburg, S. J. et al. Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barr\u00e9 syndrome. eBioMedicine 102, 105072 (2024).","journal-title":"eBioMedicine"},{"key":"580_CR154","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ana.21976","volume":"67","author":"C Walgaard","year":"2010","unstructured":"Walgaard, C. et al. Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann. Neurol. 67, 781\u2013787 (2010). An article describing a model to predict the risk of respiratory insufficiency in patients with GBS, which has subsequently been externally validated and adjusted for international applicability.","journal-title":"Ann. Neurol."},{"key":"580_CR155","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/ana.26312","volume":"91","author":"AY Doets","year":"2022","unstructured":"Doets, A. Y. et al. International validation of the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score. Ann. Neurol. 91, 521\u2013531 (2022).","journal-title":"Ann. Neurol."},{"key":"580_CR156","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp-2022-329937","volume":"94","author":"LWG Luijten","year":"2023","unstructured":"Luijten, L. W. G. et al. Modified erasmus GBS respiratory insufficiency score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 94, 300\u2013308 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR157","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","volume":"76","author":"C Walgaard","year":"2011","unstructured":"Walgaard, C. et al. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76, 968\u2013975 (2011). An article describing a prognostic model to predict the ability of patients with GBS to walk at several time points (modified Erasmus GBS Outcome Score), which has subsequently been externally validated and adapted for international applicability.","journal-title":"Neurology"},{"key":"580_CR158","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000013139","volume":"98","author":"AY Doets","year":"2022","unstructured":"Doets, A. Y. et al. Predicting outcome in guillain-barre syndrome: international validation of the modified erasmus GBS outcome score. Neurology 98, e518\u2013e532 (2022).","journal-title":"Neurology"},{"key":"580_CR159","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/acn3.51627","volume":"9","author":"N Papri","year":"2022","unstructured":"Papri, N. et al. Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh. Ann. Clin. Transl. Neurol. 9, 1264\u20131275 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"580_CR160","first-page":"CD002063","volume":"2014","author":"RA Hughes","year":"2014","unstructured":"Hughes, R. A., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst. Rev. 2014, CD002063 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"580_CR161","first-page":"CD001798","volume":"2","author":"S Chevret","year":"2017","unstructured":"Chevret, S., Hughes, R. A. & Annane, D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst. Rev. 2, CD001798 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"580_CR162","first-page":"CD008630","volume":"1","author":"AY Doets","year":"2020","unstructured":"Doets, A. Y., Hughes, R. A., Brassington, R., Hadden, R. D. & Pritchard, J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst. Rev. 1, CD008630 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"580_CR163","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/WNL.37.5.837","volume":"37","author":"M Farkkila","year":"1987","unstructured":"Farkkila, M., Kinnunen, E., Haapanen, E. & Iivanainen, M. Guillain-Barre syndrome: quantitative measurement of plasma exchange therapy. Neurology 37, 837\u2013840 (1987).","journal-title":"Neurology"},{"key":"580_CR164","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S0140-6736(84)91341-2","volume":"1","author":"RJ Greenwood","year":"1984","unstructured":"Greenwood, R. J. et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1, 877\u2013879 (1984).","journal-title":"Lancet"},{"key":"580_CR165","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","volume":"35","author":"The Guillain-Barr\u00e9 syndrome Study Group.","year":"1985","unstructured":"The Guillain-Barr\u00e9 syndrome Study Group. Plasmapheresis and acute Guillain-Barr\u00e9 syndrome.\u00a0Neurology 35, 1096\u20131104 (1985).","journal-title":"Neurology"},{"key":"580_CR166","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ana.410220612","volume":"22","author":"French Cooperative Group on Plasma Exchange in Guillain-Barrk Syndrome.","year":"1987","unstructured":"French Cooperative Group on Plasma Exchange in Guillain-Barrk Syndrome. Efficiency of plasma exchange in Guillain-Barr\u00e9 syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann. Neurol. 22, 753\u2013761 (1987).","journal-title":"Ann. Neurol."},{"key":"580_CR167","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.410410304","volume":"41","author":"The French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome.","year":"1997","unstructured":"The French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann. Neurol. 41, 298\u2013306 (1997).","journal-title":"Ann. Neurol."},{"key":"580_CR168","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0140-6736(84)90819-5","volume":"2","author":"PO Osterman","year":"1984","unstructured":"Osterman, P. O. et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2, 1296\u20131299 (1984).","journal-title":"Lancet"},{"key":"580_CR169","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group.","year":"1997","unstructured":"Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 349, 225\u2013230 (1997). A randomized controlled trial comparing the efficacy of plasma exchange and IVIg for the treatment of GBS.","journal-title":"Lancet"},{"key":"580_CR170","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1212\/WNL.46.1.100","volume":"46","author":"V Bril","year":"1996","unstructured":"Bril, V. et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 46, 100\u2013103 (1996).","journal-title":"Neurology"},{"key":"580_CR171","first-page":"263","volume":"19","author":"JR Chaudhuri","year":"2014","unstructured":"Chaudhuri, J. R. et al. Clinical outcome of Guillain-Barre syndrome with various treatment methods and cost effectiveness: a study from tertiary care center in South India: Yashoda GBS Registry. Neurol. Asia 19, 263\u2013270 (2014).","journal-title":"Neurol. Asia"},{"key":"580_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/cc10305","volume":"15","author":"MA El-Bayoumi","year":"2011","unstructured":"El-Bayoumi, M. A. et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barre syndrome: a randomized study. Crit. Care 15, R164 (2011).","journal-title":"Crit. Care"},{"key":"580_CR173","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Meche","year":"1992","unstructured":"van der Meche, F. G. & Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N. Engl. J. Med. 326, 1123\u20131129 (1992).","journal-title":"N. Engl. J. Med."},{"key":"580_CR174","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RA Hughes","year":"2007","unstructured":"Hughes, R. A. et al. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 130, 2245\u20132257 (2007).","journal-title":"Brain"},{"key":"580_CR175","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1542\/peds.2004-1324","volume":"116","author":"R Korinthenberg","year":"2005","unstructured":"Korinthenberg, R., Schessl, J., Kirschner, J. & Monting, J. S. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics 116, 8\u201314 (2005).","journal-title":"Pediatrics"},{"key":"580_CR176","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"2","author":"RA Hughes","year":"1978","unstructured":"Hughes, R. A., Newsom-Davis, J. M., Perkin, G. D. & Pierce, J. M. Controlled trial prednisolone in acute polyneuropathy. Lancet 2, 750\u2013753 (1978).","journal-title":"Lancet"},{"key":"580_CR177","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/jnnp-2020-325815","volume":"92","author":"C Verboon","year":"2021","unstructured":"Verboon, C. et al. Intravenous immunoglobulin treatment for mild Guillain-Barre syndrome: an international observational study. J. Neurol. Neurosurg. Psychiatry 92, 1080\u20131088 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR178","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","volume":"91","author":"C Verboon","year":"2020","unstructured":"Verboon, C. et al. Original research: second IVIg course in Guillain-Barre syndrome with poor prognosis: the non-randomised ISID study. J. Neurol. Neurosurg. Psychiatry 91, 113\u2013121 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR179","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000007719","volume":"93","author":"C Verboon","year":"2019","unstructured":"Verboon, C. et al. Current treatment practice of Guillain-Barre syndrome. Neurology 93, e59\u2013e76 (2019).","journal-title":"Neurology"},{"key":"580_CR180","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","volume":"20","author":"C Walgaard","year":"2021","unstructured":"Walgaard, C. et al. Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 20, 275\u2013283 (2021). A randomized clinical trial comparing treatment with one standard dose of IVIg to two doses of IVIg in patients with severe disease symptoms.","journal-title":"Lancet Neurol."},{"key":"580_CR181","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh, P. Y. K. et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. Eur. J. Neurol. 28, 3556\u20133583 (2021).","journal-title":"Eur. J. Neurol."},{"key":"580_CR182","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJM199204233261706","volume":"326","author":"AH Ropper","year":"1992","unstructured":"Ropper, A. H. The Guillain-Barre syndrome. N. Engl. J. Med. 326, 1130\u20131136 (1992).","journal-title":"N. Engl. J. Med."},{"key":"580_CR183","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00415-006-0962-9","volume":"253","author":"MP Garssen","year":"2006","unstructured":"Garssen, M. P., van Doorn, P. A. & Visser, G. H. Nerve conduction studies in relation to residual fatigue in Guillain-Barre syndrome. J. Neurol. 253, 851\u2013856 (2006).","journal-title":"J. Neurol."},{"key":"580_CR184","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2004.09.021","volume":"227","author":"A Forsberg","year":"2004","unstructured":"Forsberg, A. et al. Impairment in Guillain-Barre syndrome during the first 2 years after onset: a prospective study. J. Neurol. Sci. 227, 131\u2013138 (2004).","journal-title":"J. Neurol. Sci."},{"key":"580_CR185","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp.2004.046227","volume":"77","author":"MP Garssen","year":"2006","unstructured":"Garssen, M. P. et al. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J. Neurol. Neurosurg. Psychiatry 77, 61\u201365 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR186","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00018-009-0184-2","volume":"67","author":"JM de Vries","year":"2010","unstructured":"de Vries, J. M., Hagemans, M. L., Bussmann, J. B., van der Ploeg, A. T. & van Doorn, P. A. Fatigue in neuromuscular disorders: focus on Guillain-Barre syndrome and Pompe disease. Cell Mol. Life Sci. 67, 701\u2013713 (2010).","journal-title":"Cell Mol. Life Sci."},{"key":"580_CR187","volume":"12","author":"C Hillyar","year":"2020","unstructured":"Hillyar, C. & Nibber, A. Psychiatric sequelae of Guillain-Barre syndrome: towards a multidisciplinary team approach. Cureus 12, e7051 (2020).","journal-title":"Cureus"},{"key":"580_CR188","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00415-010-5653-x","volume":"257","author":"F Khan","year":"2010","unstructured":"Khan, F., Pallant, J. F., Ng, L. & Bhasker, A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J. Neurol. 257, 2024\u20132031 (2010).","journal-title":"J. Neurol."},{"key":"580_CR189","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/09638280701352626","volume":"30","author":"SO Demir","year":"2008","unstructured":"Demir, S. O. & Koseoglu, F. Factors associated with health-related quality of life in patients with severe Guillain-Barre syndrome. Disabil. Rehabil. 30, 593\u2013599 (2008).","journal-title":"Disabil. Rehabil."},{"key":"580_CR190","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00415-005-0958-x","volume":"253","author":"A Bersano","year":"2006","unstructured":"Bersano, A. et al. Long term disability and social status change after Guillain-Barre syndrome. J. Neurol. 253, 214\u2013218 (2006).","journal-title":"J. Neurol."},{"key":"580_CR191","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(02)00158-2","volume":"201","author":"RA Bernsen","year":"2002","unstructured":"Bernsen, R. A., de Jager, A. E., Schmitz, P. I. & van der Meche, F. G. Long-term impact on work and private life after Guillain-Barre syndrome. J. Neurol. Sci. 201, 13\u201317 (2002).","journal-title":"J. Neurol. Sci."},{"key":"580_CR192","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1529-8027.2009.00238.x","volume":"14","author":"SI Van Nes","year":"2009","unstructured":"Van Nes, S. I. et al. Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J. Peripher. Nerv. Syst. 14, 268\u2013278 (2009).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR193","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/jns5.12051","volume":"19","author":"SK Darweesh","year":"2014","unstructured":"Darweesh, S. K. et al. Health-related quality of life in Guillain-Barre syndrome patients: a systematic review. J. Peripher. Nerv. Syst. 19, 24\u201335 (2014).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR194","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1212\/WNL.59.1.84","volume":"59","author":"IS Merkies","year":"2002","unstructured":"Merkies, I. S. et al. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 59, 84\u201391 (2002).","journal-title":"Neurology"},{"key":"580_CR195","doi-asserted-by":"publisher","first-page":"108026","DOI":"10.1016\/j.clineuro.2023.108026","volume":"235","author":"EM Khedr","year":"2023","unstructured":"Khedr, E. M., Mahmoud, D. M., Ahmed, G. K. & Haridy, N. A. Predictors of long-term health-related quality of life in Guillain-Barr\u00e9 syndrome: a hospital-based study. Clin. Neurol. Neurosurg. 235, 108026 (2023).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"580_CR196","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clinph.2021.12.014","volume":"138","author":"S Arends","year":"2022","unstructured":"Arends, S. et al. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: differences in methods and reference values. Clin. Neurophysiol. 138, 231\u2013240 (2022).","journal-title":"Clin. Neurophysiol."},{"key":"580_CR197","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jns.12504","volume":"27","author":"S Arends","year":"2022","unstructured":"Arends, S. et al. Electrodiagnostic subtyping in Guillain-Barre syndrome: use of criteria in practice based on a survey study in IGOS. J. Peripher. Nerv. Syst. 27, 197\u2013205 (2022).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR198","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16335","volume":"31","author":"S Arends","year":"2024","unstructured":"Arends, S. et al. Electrodiagnostic subtyping in Guillain-Barre syndrome patients in the International Guillain-Barre Outcome Study. Eur. J. Neurol. 31, e16335 (2024).","journal-title":"Eur. J. Neurol."},{"key":"580_CR199","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03943589 (2024)."},{"key":"580_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04701164 (2024)."},{"key":"580_CR201","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022862","volume":"8","author":"B Islam","year":"2018","unstructured":"Islam, B. et al. Small volume plasma exchange for Guillain-Barr\u00e9 syndrome in resource-limited settings: a phase II safety and feasibility study. BMJ Open 8, e022862 (2018). A phase II study on the feasibility of small-volume plasma exchange in the treatment of patients with GBS in resource-limited settings.","journal-title":"BMJ Open"},{"key":"580_CR202","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211404","volume":"14","author":"N van Leeuwen","year":"2019","unstructured":"van Leeuwen, N. et al. Efficient design and analysis of randomized controlled trials in rare neurological diseases: an example in Guillain-Barr\u00e9 syndrome. PLoS ONE\u00a014, e0211404 (2019).","journal-title":"PLoS ONE"},{"key":"580_CR203","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpn.2023.02.007","volume":"44","author":"J Roodbol","year":"2023","unstructured":"Roodbol, J. et al. Predicting respiratory failure and outcome in pediatric Guillain-Barr\u00e9 syndrome. Eur. J. Paediatr. Neurol. 44, 18\u201324 (2023).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"580_CR204","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R van Koningsveld","year":"2007","unstructured":"van Koningsveld, R., Steyerberg, E. W., Hughes, R. A., Swan, A. V., van Doorn, P. A. & Jacobs, B. C. A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome. Lancet Neurol. 6, 589\u2013594 (2007).","journal-title":"Lancet Neurol."},{"key":"580_CR205","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000047956","volume":"47","author":"H Weiss","year":"2002","unstructured":"Weiss, H., Rastan, V., Mullges, W., Wagner, R. F. & Toyka, K. V. Psychotic symptoms and emotional distress in patients with Guillain-Barre syndrome. Eur. Neurol. 47, 74\u201378 (2002).","journal-title":"Eur. Neurol."},{"key":"580_CR206","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000893","volume":"2","author":"T Sharshar","year":"2012","unstructured":"Sharshar, T. et al. Relevance of anxiety in clinical practice of Guillain-Barre syndrome: a cohort study.BMJ Open 2, e000893 (2012).","journal-title":"BMJ Open"},{"key":"580_CR207","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1600-0404.2012.01688.x","volume":"127","author":"K Karkare","year":"2013","unstructured":"Karkare, K., Sinha, S., Taly, A. B. & Rao, S. Prevalence and profile of sleep disturbances in Guillain-Barre syndrome: a prospective questionnaire-based study during 10 days of hospitalization. Acta Neurol. Scand. 127, 116\u2013123 (2013).","journal-title":"Acta Neurol. Scand."},{"key":"580_CR208","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3109\/00207454.2015.1080699","volume":"126","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. The study of sleep disorder factors in patients with Guillain-Barre syndrome. Int. J. Neurosci. 126, 893\u2013898 (2016).","journal-title":"Int. J. Neurosci."},{"key":"580_CR209","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4103\/0972-2327.138521","volume":"17","author":"P Ranjani","year":"2014","unstructured":"Ranjani, P. et al. Prevalence of fatigue in Guillain-Barre syndrome in neurological rehabilitation setting. Ann. Indian Acad. Neurol. 17, 331\u2013335 (2014).","journal-title":"Ann. Indian Acad. Neurol."},{"key":"580_CR210","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jns.2012.01.024","volume":"316","author":"VE Drory","year":"2012","unstructured":"Drory, V. E., Bronipolsky, T., Bluvshtein, V., Catz, A. & Korczyn, A. D. Occurrence of fatigue over 20 years after recovery from Guillain-Barre syndrome. J. Neurol. Sci. 316, 72\u201375 (2012).","journal-title":"J. Neurol. Sci."},{"key":"580_CR211","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1191\/0269215505cr918oa","volume":"19","author":"A Forsberg","year":"2005","unstructured":"Forsberg, A., Press, R., Einarsson, U., de Pedro-Cuesta, J. & Holmqvist, L. W. Disability and health-related quality of life in Guillain-Barre syndrome during the first two years after onset: a prospective study. Clin. Rehabil. 19, 900\u2013909 (2005).","journal-title":"Clin. Rehabil."},{"key":"580_CR212","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0404.1987.tb07901.x","volume":"75","author":"K Radhakrishnan","year":"1987","unstructured":"Radhakrishnan, K., el-Mangoush, M. A. & Gerryo, S. E. Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. Acta Neurol. Scand. 75, 95\u2013100 (1987).","journal-title":"Acta Neurol. Scand."},{"key":"580_CR213","first-page":"100302","volume":"18","author":"P Zheng","year":"2021","unstructured":"Zheng, P., Tian, D. C., Xiu, Y., Wang, Y. & Shi, F. D. Incidence of Guillain-Barr\u00e9 syndrome (GBS) in China: a national population-based study.\u00a0Lancet Reg. Health West Pac. 18, 100302 (2021).","journal-title":"Lancet Reg. Health West Pac."},{"key":"580_CR214","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000430917","volume":"44","author":"WC Huang","year":"2015","unstructured":"Huang, W. C., Lu, C. L. & Chen, S. C. A 15-year nationwide epidemiological analysis of Guillain-Barr\u00e9 syndrome in Taiwan. Neuroepidemiology 44, 249\u2013254 (2015).","journal-title":"Neuroepidemiology"},{"key":"580_CR215","first-page":"1305","volume":"67","author":"H Yoshikawa","year":"2015","unstructured":"Yoshikawa, H. Epidemiology of Guillain-Barre Syndrome [Japanese].\u00a0Brain Nerve 67, 1305\u20131311 (2015).","journal-title":"Brain Nerve"},{"key":"580_CR216","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/08830738030180110801","volume":"18","author":"MR Molinero","year":"2003","unstructured":"Molinero, M. R., Varon, D., Holden, K. R., Sladky, J. T., Molina, I. B. & Cleaves, F. Epidemiology of childhood Guillain-Barr\u00e9 syndrome as a cause of acute flaccid paralysis in Honduras: 1989-1999. J. Child Neurol. 18, 741\u2013747 (2003).","journal-title":"J. Child Neurol."},{"key":"580_CR217","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1529-8027.2007.00150.x","volume":"12","author":"HC Lehmann","year":"2007","unstructured":"Lehmann, H. C., K\u00f6hne, A., Meyer zu H\u00f6rste, G. & Kieseier, B. C. Incidence of Guillain-Barr\u00e9 syndrome in Germany. J. Peripher. Nerv. Syst. 12, 285 (2007).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR218","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/jns.12239","volume":"22","author":"JOT Sipil\u00e4","year":"2017","unstructured":"Sipil\u00e4, J. O. T., Soilu-H\u00e4nninen, M., Ruuskanen, J. O., Rautava, P. & Kyt\u00f6, V. Epidemiology of Guillain-Barr\u00e9 syndrome in Finland 2004-2014. J. Peripher. Nerv. Syst. 22, 440\u2013445 (2017).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR219","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1529-8027.2011.00356.x","volume":"16","author":"NA van der Maas","year":"2011","unstructured":"van der Maas, N. A. et al. Guillain-Barr\u00e9 syndrome: background incidence rates in the Netherlands. J. Peripher. Nerv. Syst. 16, 243\u2013249 (2011).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"580_CR220","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000090916","volume":"15","author":"V Nagarajan","year":"2006","unstructured":"Nagarajan, V. & Al-Shubaili, A. Clinical and neurophysiological pattern of Guillain-Barr\u00e9 syndrome in Kuwait. Med. Princ. Pract. 15, 120\u2013125 (2006).","journal-title":"Med. Princ. Pract."},{"key":"580_CR221","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s10072-021-05562-y","volume":"43","author":"M Hosseininezhad","year":"2022","unstructured":"Hosseininezhad, M. et al. Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barr\u00e9 syndrome in the north of Iran. Neurol. Sci. 43, 1929\u20131938 (2022).","journal-title":"Neurol. Sci."},{"key":"580_CR222","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007622","volume":"13","author":"A Capasso","year":"2019","unstructured":"Capasso, A., Ompad, D. C., Vieira, D. L., Wilder-Smith, A. & Tozan, Y. Incidence of Guillain-Barr\u00e9 Syndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: a systematic review and meta-analysis.\u00a0PLoS Negl. Trop. Dis. 13, e0007622 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"580_CR223","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5694\/j.1326-5377.1987.tb120153.x","volume":"146","author":"GJ Hankey","year":"1987","unstructured":"Hankey, G. J. Guillain-Barr\u00e9 syndrome in Western Australia, 1980-1985. Med. J. Aust. 146, 130\u2013133 (1987).","journal-title":"Med. J. Aust."},{"key":"580_CR224","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1212\/WNL.56.11.1467","volume":"56","author":"R van Koningsveld","year":"2001","unstructured":"van Koningsveld, R. et al. Gastroenteritis-associated Guillain-Barr\u00e9 syndrome on the Caribbean island Cura\u00e7ao. Neurology 56, 1467\u20131472 (2001).","journal-title":"Neurology"},{"key":"580_CR225","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/ana.410360609","volume":"36","author":"DE Hart","year":"1994","unstructured":"Hart, D. E., Rojas, L. A., Ros\u00e1rio, J. A., Recalde, H. & Rom\u00e1n, G. C. Childhood Guillain-Barr\u00e9 syndrome in Paraguay, 1990 to 1991. Ann. Neurol. 36, 859\u2013863 (1994).","journal-title":"Ann. Neurol."},{"key":"580_CR226","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jns.2017.04.006","volume":"377","author":"JL Salinas","year":"2017","unstructured":"Salinas, J. L. et al. Incidence and clinical characteristics of Guillain-Barr\u00e9 syndrome before the introduction of Zika virus in Puerto Rico. J. Neurol. Sci. 377, 102\u2013106 (2017).","journal-title":"J. Neurol. Sci."},{"key":"580_CR227","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/jnnp.2007.123943","volume":"79","author":"A Makowska","year":"2008","unstructured":"Makowska, A. et al. Immune responses to myelin proteins in Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 79, 664\u2013671 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR228","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200047","volume":"10","author":"AJ Davies","year":"2022","unstructured":"Davies, A. J. et al. Guillain-Barre syndrome following zika virus infection is associated with a diverse spectrum of peripheral nerve reactive antibodies.\u00a0Neurol. Neuroimmunol. Neuroinflamm. 10, e200047 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"580_CR229","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/jnnp-2021-326343","volume":"92","author":"J Fehmi","year":"2021","unstructured":"Fehmi, J. et al. IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality. J. Neurol. Neurosurg. Psychiatry 92, 1089\u20131095 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"580_CR230","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/brain\/awab014","volume":"144","author":"E Pascual-Goni","year":"2021","unstructured":"Pascual-Goni, E. et al. Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 144, 1183\u20131196 (2021).","journal-title":"Brain"}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00580-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00580-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T04:02:55Z","timestamp":1734580975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-024-00580-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":230,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1038\/s41572-024-00580-4","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"13 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.E.L. declares no competing interests. N.P. declares no competing interests. N.S. declares no competing interests. S.R. reports institutional funding for research related to Guillain\u2013Barr\u00e9 syndrome (GBS) from the Wellcome Trust, Medical Research Council (UK) and GBS-CIDP Foundation International. He has undertaken consultancies for argenx, Hansa Biopharma, Dainthus and Annexon related to the treatment of inflammatory neuropathies. He is a member of the IGOS biobank committee and of the Medical Advisory Board of the GBS and related inflammatory neuropathies (GAIN) patient support group. L.Q. received research grants from Instituto de Salud Carlos III \u2013 Ministry of Economy and Innovation (Spain), CIBERER, Fundaci\u00f3 La Marat\u00f3, GBS-CIDP Foundation International, UCB, argenx and Grifols. L.Q. received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi Genzyme, Merck, Annexon, Alnylam, Janssen, argenx, UCB, Dianthus, LFB, Avilar Therapeutics, Nuvig Therapeutics, Takeda and Roche. L.Q. serves at the Clinical Trial Steering Committees for Sanofi Genzyme and argenx, and was Principal Investigator for UCB\u2019s CIDP01 trial. L.Q. is a member of the Steering Committee of IGOS. B.C.J. reports institutional funding for research related to GBS from Prinses Beatrix Spierfonds, Zon-MW, GBS-CIDP Foundation International, Horizon 2020, Grifols, CSL Behring, Annexon, Roche and Hansa Biopharma. B.C.J. is in the Clinical Trial Committee of Annexon. B.C.J. serves as the chair of the Steering Committee of IGOS and is a member of the Global Medical Advisory Board of the GBS-CIDP Foundation International.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}